Cassava Sciences, Inc. (SAVA)

NASDAQ: SAVA · Delayed Price · USD
45.88
0.19 (0.42%)
At close: Jan 14, 2022 4:00 PM
45.89
0.01 (0.02%)
After-hours:Jan 14, 2022 7:59 PM EST

Company Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc.
CountryUnited States
Founded1998
IndustryPharmaceuticals
SectorHealth Care
Employees11
CEORemi Barbier

Contact Details

Address:
7801 N Capital of Texas Hwy Ste 260
Austin, Texas 78731-1192
United States
Phone512 501 2444
Websitepaintrials.com

Stock Details

Ticker SymbolSAVA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1069530

Key Executives

NamePosition
Remi BarbierFounder, Chairman, President and Chief Executive Officer
Eric J. SchoenChief Financial Officer
Dr. Nadav FriedmannChief Medical Officer and Director
Dr. George ThorntonSenior Vice President of Technology
Michael ZamlootSenior Vice President of Technical Operations
Dr. Lindsay H. Burns Ph.D.Senior Vice President of Neuroscience
Dr. James W. Kupiec M.D.Chief Clinical Development Officer

Latest SEC Filings

DateTypeTitle
Jan 6, 20228-KCurrent report
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 10, 20218-KCurrent report
Sep 21, 20214Statement of changes in beneficial ownership of securities
Aug 4, 202110-QQuarterly report [Sections 13 or 15(d)]
Aug 3, 20218-KCurrent report
Aug 3, 20218-KCurrent report
Jul 20, 20214Statement of changes in beneficial ownership of securities
Jun 21, 20218-KCurrent report
Jun 14, 20213Initial statement of beneficial ownership of securities
View All SEC Filings